

BIBLIOGRAPHY

- Allahabadia, A., Daykin, J., Holder, R., Sheppard, M., Gough, S. and Franklyn, J. (2000). Age and Gender Predict the Outcome of Treatment for Graves' Hyperthyroidism. *The Journal of Clinical Endocrinology & Metabolism*, 85(3), pp.1038-1042.
- Coles, A., Wing, M., Smith, S., Coraddu, F., Greer, S., Taylor, C., Weetman, A., Hale, G., Chatterjee, V., Waldmann, H. and Compston, A. (1999). Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. *The Lancet*, 354(9191), pp.1691-1695.
- Da Silva, J. (1995). Sex hormones, glucocorticoids and autoimmunity: facts and hypotheses. *Annals of the Rheumatic Diseases*, 54(1), pp.6-16.
- Eliana, F., Suwondo, P., Harahap, A., Djauzi, S., Prihartono, J. and Pemayun, T. (2017). The Role of Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) Gene, Thyroid Stimulating Hormone Receptor (TSHR) Gene and Regulatory T-cells as Risk Factors for Relapse in Patients with Graves Disease. *Acta Medica Indonesiana*, 49(3), pp.195-204.
- Hanafusa, T., Chiovato, L., Doniach, D., Pujol-Borrell, R., Russell, R. and Bottazzo, G. (1983). ABERRANT EXPRESSION OF HLA-DR ANTIGEN ON THYROCYTES IN GRAVES' DISEASE: RELEVANCE FOR AUTOIMMUNITY. *The Lancet*, 322(8359), pp.1111-1115.
- Hussain, Y., Hookham, J., Allahabadia, A. and Balasubramanian, S. (2017). Epidemiology, management and outcomes of Graves' disease—real life data. *Endocrine*, 56(3), pp.568-578.
- Jansson, S., Berg, G., Lindstedt, G., Michanek, A. and Nystrom, E. (1993). Overweight--a common problem among women treated for hyperthyroidism. *Postgraduate Medical Journal*, 69(808), pp.107-111.
- Kimball, L., Kulinskaya, E., Brown, B., Johnston, C. and Farid, N. (2002). Does smoking increase relapse rates in Graves' disease?. *Journal of Endocrinological Investigation*, 25(2), pp.152-157.
- Laurberg, P. (2006). Remission of Graves' disease during anti-thyroid drug therapy. Time to reconsider the mechanism?. *European Journal of Endocrinology*, 155(6), pp.783-786.
- Lawgaly, S., Kallousa, H. and Gerryo, S. (2018). Predictors of relapse in graves' hyperthyroidism after treatment with antithyroid drugs. *Ibnosina Journal of Medicine and Biomedical Sciences*, 10(6), p.205.
- Liu, J., Fu, J., Xu, Y. and Wang, G. (2017). Antithyroid Drug Therapy for Graves' Disease and Implications for Recurrence. *International Journal of Endocrinology*, 2017, pp.1-8.
- LIU, L., LU, H., LIU, Y., LIU, C. and XUN, C. (2016). Predicting relapse of Graves' disease following treatment with antithyroid drugs. *Experimental and Therapeutic Medicine*, 11(4), pp.1453-1458.
- Magri, F., Zerbini, F., Gaiti, M., Capelli, V., Ragni, A., Rotondi, M. and Chiovato, L. (2016). GENDER INFLUENCES THE CLINICAL PRESENTATION AND LONG-TERM OUTCOME OF GRAVES DISEASE. *Endocrine Practice*, 22(11), pp.1336-1342.

- MARTIN, A., SCHWARTZ, A., FRIEDMAN, E. and DAVIES, T. (1989). Successful Production of Intrathyroidal Human T Cell Hybridomas: Evidence for Intact Helper T Cell Function in Graves' Disease*. *The Journal of Clinical Endocrinology & Metabolism*, 69(6), pp.1104-1108.
- Nagata, K., Nakayama, Y., Higaki, K., Ochi, M., Kanai, K., Matsushita, M., Kuwamoto, S., Kato, M., Murakami, I., Iwasaki, T., Nanba, E., Kimura, H. and Hayashi, K. (2015). Reactivation of persistent Epstein–Barr virus (EBV) causes secretion of thyrotropin receptor antibodies (TRAbs) in EBV-infected B lymphocytes with TRAbs on their surface. *Autoimmunity*, 48(5), pp.328-335.
- Rapoport, B., Aliesky, H., Chen, C. and McLachlan, S. (2015). Evidence that TSH Receptor A-Subunit Multimers, Not Monomers, Drive Antibody Affinity Maturation in Graves' Disease. *The Journal of Clinical Endocrinology & Metabolism*, 100(6), pp.E871-E875.
- Smith, T. and Hegedüs, L. (2016). Graves' Disease. *New England Journal of Medicine*, 375(16), pp.1552-1565.
- Song, R., Lin, H., Chen, Y., Zhang, X. and Feng, W. (2017). Effects of methimazole and propylthiouracil exposure during pregnancy on the risk of neonatal congenital malformations: A meta-analysis. *PLOS ONE*, 12(7), p.e0180108.
- Song, R., Wang, B., Yao, Q., Li, Q., Jia, X. and Zhang, J. (2019). The Impact of Obesity on Thyroid Autoimmunity and Dysfunction: A Systematic Review and Meta-Analysis. *Frontiers in Immunology*, 10.
- Struja, T., Fehlberg, H., Kutz, A., Guebelin, L., Degen, C., Mueller, B. and Schuetz, P. (2017). Can we predict relapse in Graves' disease? Results from a systematic review and meta-analysis. *European Journal of Endocrinology*, 176(1), pp.87-97.
- Subekti, I. and Pramono, L. (2018). *Current Diagnosis and Management of Graves' Disease*. [online] Actamedindones.org. Available at: <http://www.actamedindones.org/index.php/ijim/article/download/817/pdf> [Accessed 6 Jun. 2019].
- Tomer, Y. (2014). Mechanisms of Autoimmune Thyroid Diseases: From Genetics to Epigenetics. *Annual Review of Pathology: Mechanisms of Disease*, 9(1), pp.147-156.
- Vos, X., Endert, E., Zwinderman, A., Tijssen, J. and Wiersinga, W. (2016). Predicting the Risk of Recurrence Before the Start of Antithyroid Drug Therapy in Patients With Graves' Hyperthyroidism. *The Journal of Clinical Endocrinology & Metabolism*, 101(4), pp.1381-1389.
- Weetman, A., Yateman, M., Ealey, P., Black, C., Reimer, C., Williams, R., Shine, B. and Marshall, N. (1990). Thyroid-stimulating antibody activity between different immunoglobulin G subclasses. *Journal of Clinical Investigation*, 86(3), pp.723-727.
- Winsa, B., Dahlberg, P., Jansson, R., Ågren, H. and Karlsson, F. (1990). Factors influencing the outcome of thyrostatic drug therapy in Graves' disease. *Acta Endocrinologica*, 122(6), pp.722-728.

Zimmermann, M. and Boelaert, K. (2015). Iodine deficiency and thyroid disorders. *The Lancet Diabetes & Endocrinology*, 3(4), pp.286-295.